Rising serum lactate dehydrogenase often caused by granulocyte-or granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma

Andreas H. Sarris; Alexandro Majlis; Meletios A. Dimopoulos; Anas Younes; Forrest Swann; Maria A. Rodriguez; Peter Mclaughlin; Fernando Cabanillas

doi:10.3109/10428199509056860

Rising serum lactate dehydrogenase often caused by granulocyte-or granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma

Andreas H. Sarris, Alexandro Majlis, Meletios A. Dimopoulos, Anas Younes, Forrest Swann, Maria A. Rodriguez, Peter Mclaughlin, Fernando Cabanillas

Lymphoma-Myeloma

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Since rising serum lactate dehydrogenase (LDH) heralds progression in patients with lymphoma or myeloma we investigated the significance of its elevations during chemotherapy supported by granulocyte (G-) or Granulocyte-Macrophage (GM-) colony stimulating factors (CSF). To exclude effects of resistant disease we analyzed 52 courses of therapy in 36 responding patients. During hematologic recovery LDH increased above normal in 53% and 85% of patients with leukocyte counts of 10,000/mUL and 15,000/kmUL, respectively. After CSF discontinuation LDH fell to or towards normal during 20 courses with adequate follow-up. Therefore rising serum LDH in patients with lymphoma or myeloma may be caused the CSF administration during chemotherapy and not by progressive disease. Proper identification of this effect can prevent unnecessary tests or treatment delays.

Original language	English (US)
Pages (from-to)	473-477
Number of pages	5
Journal	Leukemia and Lymphoma
Volume	17
Issue number	5-6
DOIs	https://doi.org/10.3109/10428199509056860
State	Published - 1995

Keywords

G-CSF
GM-CSF
Lymphoma
Myeloma
Rising serum LDH

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.3109/10428199509056860

Cite this

Sarris, A. H., Majlis, A., Dimopoulos, M. A., Younes, A., Swann, F., Rodriguez, M. A., Mclaughlin, P., & Cabanillas, F. (1995). Rising serum lactate dehydrogenase often caused by granulocyte-or granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma. Leukemia and Lymphoma, 17(5-6), 473-477. https://doi.org/10.3109/10428199509056860

Rising serum lactate dehydrogenase often caused by granulocyte-or granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma. / Sarris, Andreas H.; Majlis, Alexandro; Dimopoulos, Meletios A. et al.
In: Leukemia and Lymphoma, Vol. 17, No. 5-6, 1995, p. 473-477.

Research output: Contribution to journal › Article › peer-review

Sarris, AH, Majlis, A, Dimopoulos, MA, Younes, A, Swann, F, Rodriguez, MA, Mclaughlin, P & Cabanillas, F 1995, 'Rising serum lactate dehydrogenase often caused by granulocyte-or granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma', Leukemia and Lymphoma, vol. 17, no. 5-6, pp. 473-477. https://doi.org/10.3109/10428199509056860

@article{c5149219942546c38313ebaa459ccc1f,

title = "Rising serum lactate dehydrogenase often caused by granulocyte-or granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma",

abstract = "Since rising serum lactate dehydrogenase (LDH) heralds progression in patients with lymphoma or myeloma we investigated the significance of its elevations during chemotherapy supported by granulocyte (G-) or Granulocyte-Macrophage (GM-) colony stimulating factors (CSF). To exclude effects of resistant disease we analyzed 52 courses of therapy in 36 responding patients. During hematologic recovery LDH increased above normal in 53% and 85% of patients with leukocyte counts of 10,000/mUL and 15,000/kmUL, respectively. After CSF discontinuation LDH fell to or towards normal during 20 courses with adequate follow-up. Therefore rising serum LDH in patients with lymphoma or myeloma may be caused the CSF administration during chemotherapy and not by progressive disease. Proper identification of this effect can prevent unnecessary tests or treatment delays.",

keywords = "G-CSF, GM-CSF, Lymphoma, Myeloma, Rising serum LDH",

author = "Sarris, {Andreas H.} and Alexandro Majlis and Dimopoulos, {Meletios A.} and Anas Younes and Forrest Swann and Rodriguez, {Maria A.} and Peter Mclaughlin and Fernando Cabanillas",

year = "1995",

doi = "10.3109/10428199509056860",

language = "English (US)",

volume = "17",

pages = "473--477",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "5-6",

}

TY - JOUR

T1 - Rising serum lactate dehydrogenase often caused by granulocyte-or granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma

AU - Sarris, Andreas H.

AU - Majlis, Alexandro

AU - Dimopoulos, Meletios A.

AU - Younes, Anas

AU - Swann, Forrest

AU - Rodriguez, Maria A.

AU - Mclaughlin, Peter

AU - Cabanillas, Fernando

PY - 1995

Y1 - 1995

N2 - Since rising serum lactate dehydrogenase (LDH) heralds progression in patients with lymphoma or myeloma we investigated the significance of its elevations during chemotherapy supported by granulocyte (G-) or Granulocyte-Macrophage (GM-) colony stimulating factors (CSF). To exclude effects of resistant disease we analyzed 52 courses of therapy in 36 responding patients. During hematologic recovery LDH increased above normal in 53% and 85% of patients with leukocyte counts of 10,000/mUL and 15,000/kmUL, respectively. After CSF discontinuation LDH fell to or towards normal during 20 courses with adequate follow-up. Therefore rising serum LDH in patients with lymphoma or myeloma may be caused the CSF administration during chemotherapy and not by progressive disease. Proper identification of this effect can prevent unnecessary tests or treatment delays.

AB - Since rising serum lactate dehydrogenase (LDH) heralds progression in patients with lymphoma or myeloma we investigated the significance of its elevations during chemotherapy supported by granulocyte (G-) or Granulocyte-Macrophage (GM-) colony stimulating factors (CSF). To exclude effects of resistant disease we analyzed 52 courses of therapy in 36 responding patients. During hematologic recovery LDH increased above normal in 53% and 85% of patients with leukocyte counts of 10,000/mUL and 15,000/kmUL, respectively. After CSF discontinuation LDH fell to or towards normal during 20 courses with adequate follow-up. Therefore rising serum LDH in patients with lymphoma or myeloma may be caused the CSF administration during chemotherapy and not by progressive disease. Proper identification of this effect can prevent unnecessary tests or treatment delays.

KW - G-CSF

KW - GM-CSF

KW - Lymphoma

KW - Myeloma

KW - Rising serum LDH

UR - http://www.scopus.com/inward/record.url?scp=0029027803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029027803&partnerID=8YFLogxK

U2 - 10.3109/10428199509056860

DO - 10.3109/10428199509056860

M3 - Article

C2 - 7549840

AN - SCOPUS:0029027803

SN - 1042-8194

VL - 17

SP - 473

EP - 477

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 5-6

ER -

Rising serum lactate dehydrogenase often caused by granulocyte-or granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this